By fusing a brain-targeted antibody with an antibody that protects neurons from degeneration, scientists developed a new class of drugs that can traverse the blood brain barrier, enabling potential new treatments for Parkinson’s disease, Alzheimer’s disease, and depression.
Single-nucleotide polymorphisms (SNPs) occur where a single base pair at a specific locus differs from the standard sequence. The SNP might relate to disease susceptibility, pathogenesis of disease, or efficacy of specific drugs. Identifying SNPs is useful for improving our understanding of human genetics and as a clinical diagnostic tool.
Targeting oncogenic transcription factors like MYC is challenging, but researchers found a way to target its regulator, WDR5, for degradation, exemplifying the capacity of protein degraders to target the “undruggable.”